Literature DB >> 25549691

United States comparative costs and absenteeism of diabetic ophthalmic conditions.

Richard A Brook1, Nathan L Kleinman, Sunil Patel, Jim E Smeeding, Ian A Beren, Adam Turpcu.   

Abstract

OBJECTIVE: This retrospective cohort study examined the impact of diabetic macular edema (DME), diabetic retinopathy (DR), or diabetes on annual health benefit costs and absenteeism in US employees.
METHODS: Claims data from 2001 to 2012 was extracted from the Human Capital Management Services Group Research Reference Database on annual direct/indirect health benefit costs and absences for employees aged ≥ 18 years. Employees with DME, DR, or diabetes were identified by International Classification of Diseases, Ninth Revision, Clinical Modification codes. Employees were divided into two groups, drivers or nondrivers, and examined in separate analyses. For drivers and nondrivers, the DME, DR, and diabetes cohorts were compared with their respective control groups (without diabetes). Two-part regression models controlled for demographics and job-related characteristics.
RESULTS: A total of 39,702 driver and 426,549 nondriver employees were identified as having ≥ 1 year's continuous health plan enrollment. Direct medical costs for drivers with DME, DR, or diabetes were $6470, $8021, and $5102, respectively (>2.8 times higher and statistically significant compared with driver controls). Nondrivers with DME and DR incurred significantly higher sick leave and short-term disability costs compared with the nondrivers with diabetes and nondriver controls. In drivers with DME, the majority of days of absence were for short- and long-term disability (12.41 and 11.43 days, respectively). In drivers with DR, the majority of days of absence were for short-term disability (10.70 days). In nondrivers with DME and nondrivers with DR, the majority of days of absence were for sick leave (5.74 and 4.93 days, respectively) and short-term disability (5.08 and 4.93 days, respectively).
CONCLUSION: DME and DR are associated with substantial direct medical cost and absenteeism in this real-world sample of medically insured employees. This research highlights the negative impact of DME and DR on annual costs and absenteeism and may assist employers in assessing the impact of these conditions on employees.

Entities:  

Keywords:  Cost studies; macular edema; outcomes studies; retinopathy

Mesh:

Year:  2014        PMID: 25549691     DOI: 10.1080/00325481.2014.994468

Source DB:  PubMed          Journal:  Postgrad Med        ISSN: 0032-5481            Impact factor:   3.840


  8 in total

1.  Comorbidity and health care visit burden in working-age commercially insured patients with diabetic macular edema.

Authors:  Szilárd Kiss; Hitesh S Chandwani; Ashley L Cole; Vaishali D Patel; Orsolya E Lunacsek; Pravin U Dugel
Journal:  Clin Ophthalmol       Date:  2016-12-07

2.  Factors Affecting Compliance to Anti-Vascular Endothelial Growth Factor Treatment of Diabetic Macular Edema in a Cohort of Jordanian Patients.

Authors:  Nakhleh E Abu-Yaghi; Alaa M Abed; Dana F Khlaifat; Mohammed B Nawaiseh; Laith O Emoush; Heba Z AlHajjaj; Ala M Abojaradeh; Mariana N Hattar; Sura K Abusaleem; Hashem M Sabbagh; Yazan A Abu Gharbieh; Sura A Quaqazeh
Journal:  Clin Ophthalmol       Date:  2020-03-24

3.  Direct Medical Expenditures Associated with Eye Complications among Adults with Diabetes in the United States.

Authors:  Abdulkarim M Meraya; Monira Alwhaibi; Moteb A Khobrani; Hafiz A Makeen; Saad S Alqahtani; David Banji
Journal:  J Diabetes Res       Date:  2020-05-15       Impact factor: 4.011

4.  Disability and workers' compensation trends for employees with mental disorders and SUDs in the United States.

Authors:  Richard A Brook; Nathan L Kleinman; Ian A Beren
Journal:  Ment Health Clin       Date:  2021-09-24

Review 5.  The economics of vision impairment and its leading causes: A systematic review.

Authors:  Ana Patricia Marques; Jacqueline Ramke; John Cairns; Thomas Butt; Justine H Zhang; Iain Jones; Marty Jovic; Allyala Nandakumar; Hannah Faal; Hugh Taylor; Andrew Bastawrous; Tasanee Braithwaite; Serge Resnikoff; Peng T Khaw; Rupert Bourne; Iris Gordon; Kevin Frick; Matthew J Burton
Journal:  EClinicalMedicine       Date:  2022-03-22

6.  Phase 1 Study of THR-687, a Novel, Highly Potent Integrin Antagonist for the Treatment of Diabetic Macular Edema.

Authors:  Arshad M Khanani; Sunil S Patel; Victor H Gonzalez; Suk J Moon; Glenn J Jaffe; John A Wells; Petra Kozma; Pravin U Dugel; Raj K Maturi
Journal:  Ophthalmol Sci       Date:  2021-07-14

7.  A Multicenter, Cross-Sectional Study of the Incidence of Major Macular Diseases That Cause Visual Impairment and Require Therapeutic Intervention in Greece: The ADVICE Study.

Authors:  Dimitrios A Karagiannis; Meropi Lygerou; Georgios Papadopoulos; Stamatina A Kabanarou; Miltiadis Aspiotis; Doukas C Dardabounis; Panagiotis G Minakakis; Sofia I Spai; Chrysanthi Koutsandrea; Panagiotis Oikonomidis; Georgia N Pantelopoulou; Olga C Kousidou; Miltiadis Tsilimbaris
Journal:  Clin Ophthalmol       Date:  2020-05-25

8.  Biomarkers and predictors for functional and anatomic outcomes for small gauge pars plana vitrectomy and peeling of the internal limiting membrane in naïve diabetic macular edema: The VITAL Study.

Authors:  Matias Iglicki; Alejandro Lavaque; Malgorzata Ozimek; Hermino Pablo Negri; Mali Okada; Jay Chhablani; Catharina Busch; Anat Loewenstein; Dinah Zur
Journal:  PLoS One       Date:  2018-07-11       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.